Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes

Sara Lázaro, Miriam Pérez-Crespo, Corina Lorz, Alejandra Bernardin, Marta Oteo, Ana Belén Enguita, Eduardo Romero, Pilar Hernández, Laura Tomás, Miguel Ángel Morcillo, Jesús M. Paramio, and Mirentxu Santos

High-grade neuroendocrine lung malignancies (large-cell neuroendocrine cell carcinoma, LCNEC, and small-cell lung carcinoma, SCLC) are among the most deadly lung cancer conditions with no optimal clinical management. The relationships between SCLC and LCNEC are still largely unknown and a current matter of debate as growing molecular data raise new therapeutic possibilities. Here we describe murine models of high-grade neuroendocrine lung carcinomas generated by the loss of 4 tumor suppressor genes. In an Rb1-null background, deletion of Rb1, Pten, and Trp53 slowed alveolar cell proliferation following Ad-CMVcre infection in a wide variety of epithelial cells, producing LCNEC. Meanwhile, inactivation of these genes using Ad-KScr in basal cells leads to the development of SCLC, thus differentially influencing the lung cancer type. So far, a defined model of LCNEC has not been reported. Molecular and transcriptomic analyses of both models revealed strong similarities to their human counterparts. In addition, a 64Ga-DOTATOC-based molecular-imaging method provides a tool for detection and monitoring the progression of the cancer. These data offer insight into the biology of SCLC and LCNEC, providing a useful framework for development of compounds and preclinical investigations in accurate immunocompetent models.

Author contributions: C.L., J.M.P., and M.S. designed research; S.L., M.P.C., M.O., E.R., P.H., and M.S. performed research; L.T. and M.S. contributed new reagents/analytic tools; S.L., M.P.C., C.L., A.B., M.O., A.B.E., E.R., M.A.M., J.M.P., and M.S. analyzed data; and C.L., A.B., M.O., M.A.M., J.M.P., and M.S. wrote the paper.

The authors declare no competing interest.

This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

Data deposition: Data related to this paper have been deposited in the Sequence Read Archive (SRA) database (accession no. PRJNA507341) and Gene Expression Omnibus (GEO) database (accession no. GSE121574).

1M.P.C. and C.L. contributed equally to this work.

2To whom correspondence may be addressed. Email: mirentxu.santos@ciemat.es.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1821745116/-/DCSupplemental.

First published October 14, 2019.
Ga-DOTA-peptides show higher sensitivity for tumor detection (10, 11). Therefore, in addition to conventional imaging, SSTRTargeted imaging could be applied to detect and functionally characterize neuroendocrine tumors.

Mutations in TP53 and RB1 are characteristic of human SCLC and LCNEC. Pten alterations have been identified in SCLC (4, 12). Thus, mouse models of SCLC have been generated by deletion of these genes in different lung compartments. RB1 mutations have been found in 3.64% of SCLC (12). As we have previously shown the tumor suppressor activities of Rb1l in other tumoral types (13–15), we now interrogate the role of Rb1l in the development of high-grade neuroendocrine lung carcinoma. In this study, we have used a 4 tumor suppressor-based, quadruple knock out (QKO) mouse model that upon cre-mediated recombination in an Rb1l-null background results in the additional ablation of Rb1, Pten, and Trp53 in adult lungs. Combined ablation of these genes leads to the development of high-grade malignant neuroendocrine lung carcinomas strikingly similar to human disease. Our results indicate that induction of the same genetic alterations in different cell types produces different tumor types and that keratin 5 expressing basal cells have the ability to give rise to SCLC. We have taken advantage of the models generated to develop a noninvasive in vivo diagnosis and follow-up system of the neuroendocrine lesions developed.

Results

Targeting Widely Versus Specifically Epithelial Cells in the Lung. Adeno-cre intratracheal infection has proven to be a robust method of modeling lung cancer in mice (16). We used 2 different approaches: on the one hand we used conventional cytomegalovirus promoter, Ad5-CMVcre, which targets most lung cell types (17) (SI Appendix, Fig. S1 A–E); on the other hand, we used an adenovirus (Ad5-KScre) in which cre recombinase is under the control of keratin K5 promoter (18). This approach is based on the ability of proximal airway basal cells to self-renew and give rise to other cellular types (6, 7, 19) and has been reported to target lung basal cells (8). Cre activity was traced using reporter ROSA26R-ttdTomato (20) and ROSA26R-LacZ mice (21) in the absence of any stimuli. Immunostaining with an antikeratin K5 antibody showed coexpression with ttdTomato protein in scattered basal cells, mainly in bronchi of Ad5-KScre–infected animals (SI Appendix, Fig. S1 A–E). Colocalization with LacZ confirmed basal cell cre recombination (SI Appendix, Fig. S1 A′–E′). In contrast to Ad5-KScre targeting (SI Appendix, Fig. S1 B′–E′ and B′–E′), Ad5-CMVcre show coexpression with other markers of lung lineage (alveolar-, club-, or neuroendocrine-type cells) (SI Appendix, Fig. S1 B–E).

Wide Versus Specific Ablation of 4 Tumor Suppressor Genes (Rb1, Rb1l, Pten, and Trp53) in Lungs. Next, we infected adult Rb1+/−;Rbl1−/−;Trp53+/−;Pten+/− mice with Ad5-CMVcre (CMV-QKO mice) or Ad5-KScre (K5-QKO mice) (Fig. 1A). Both groups of mice developed lung tumors (87 and 84%, respectively). Most CMV-QKO mice (n = 67) had to be killed within 2 to 3 mo because of tumor burden, as they developed lung tumors with a median survival of 11 wk. K5-QKO mice were killed within 4 to 5 mo after Ad5-KScre infection (n = 67; median survival, 17 wk) (Fig. 1B). None of the control mice (n = 30) developed any lesion. Tumor genotyping by PCR revealed the ablation of Rb1, Trp53, and Pten and the absence of Rb1l further confirmed by RT-qPCR and immunohistochemistry (SI Appendix, Fig. S2).

We observed that 57% of the tumors developed in the CMV-QKO mice (total number of tumors, n = 886; mean number of tumors per mouse, mean ± SEM = 13.42 ± 1.65) (Fig. 1C, SI Appendix, Fig. S3, and Dataset S1) shared morphological traits with human LCNEC (Fig. 1D), such as large cell size, abundant cytoplasm, frequent presence of nucleoli, and neuroendocrine morphology (Figs. 1D and 2B). In 6 out of 67 cases we also observed adenocarcinomas in addition to neuroendocrine tumors (SI Appendix, Table S1). Strikingly, in the Ad5-KScre–infected group a different tumor spectrum was detected. In K5-QKO mice, 79% of the tumors developed (total number of tumors, n = 537; mean ± SEM = 8.01 ± 1.35) (Fig. 1C, SI Appendix, Fig. S3, and Dataset S1) were characterized by small-size cells with scant cytoplasm (see Figs. 1D, 2C, and 4C), resembling human SCLC. These findings were further confirmed by immunohistochemical expression of markers in parallel with human LCNEC and SCLC (positive Chromogranin A, TTF1, and CGRP [Fig. 1D] and negative CC10 and proSPC expression [not shown]).

No significant differences in tumor size were observed at median survival time for each model (SI Appendix, Fig. S3B). CMV-QKO and K5-QKO tumors were characterized by high proliferation, scattered expression of cyclin D1, absence of p19, and activation of Stat3 and Akt (Fig. 2A). Notably, tumors in both groups were negative for keratin 5 expression, indicating that during tumor progression after inactivation of the targeted tumor suppressor genes, tumor cells evolve lacking some of their initial characteristics. Nonetheless, according to the initial targeted cell type, we observed a different localization in the lung: CMV-QKO mice develop LCNEC with a predominant parenchymal location, whereas K5-QKO mice develop tumors mainly in proximal bronchi (Fig. 2B), similar to the corresponding human tumors.

We performed complete analyses in search of metastases and observed a different metastatic spreading. CMV-QKO mice did not develop any other pathology outside the lungs. In contrast, in liver and/or ganglia in 15 out of 31 analyzed K5-QKO mice, metastases were observed displaying histological features and neuroendocrine markers expression similar to primary lung tumors (Fig. 2C), resembling the metastatic behavior of human SCLC.

Altogether, these observations indicate that the tumors growing in the lung of CMV-QKO mice provide a robust model for LCNEC. The data also show that Ad5-KScre–targeted basal cells can initiate SCLC tumors after suppression of Rb1, Pten, and Trp53 in an Rb1l-null background, providing evidence that this specific cell type contributes to the development of SCLC.

Genomic Analysis of More SCLC and Mouse LCNEC Tumors. To further characterize the LCNEC tumors arising from CMV-QKO (moLCNEC) and SCLC tumors arising from K5-QKO (moSCLC) mice, we performed whole-transcriptome analysis of mouse tumors and control (uninfected Rb1+/−;Rbl1−/−;Trp53+/−;Pten+/− lung samples (moLung). The principal component analysis (PCA) of the transcriptomes showed that moLCNEC displayed high intragroup heterogeneity (Fig. 3A and SI Appendix, Fig. S4A) similar to that reported for human LCNEC (2–4). Among the 3 groups, moLung and moSCLC diverged the most along the principal component 1 (PC1) axis. The comparison of moSCLC or moLCNEC gene expression versus moLung (Fig. 3B and Dataset S2) confirmed this difference, supporting that the transcriptional impact of the Rb1, Pten, and Trp53 gene deletion in the absence of Rb1l was greater in the moSCLC than in the moLCNEC. The up-regulated common genes to moLCNEC and moSCLC are primarily involved in cell cycle and mitotic progression (Fig. 3C and Dataset S3), consistent with the high mitotic rate of these tumors (Fig. 24). Down-regulated genes in both tumors are involved in vasculo genesis and angiogenesis, as well as signaling pathways such as MAPK, TGF-beta receptor, BMP, PI3K, or NF-kappaB (SI Appendix, Fig. S4B and Dataset S3). moSCLC showed specific up-regulation of markers commonly found human SCLC tumors, including neuroendocrine markers (ASCL1, ChGA, SCG3, NCAM1, SOX1, SYN1, SYP, ELAV3, ELAV4), while moLCNEC showed up-regulation of genes involved in immune response, keratinocyte differentiation (CALML3), and PHD3 (Egln3), an oxygen sensor recently involved in the modulation of metastasis and resistance to EGFR inhibitors in lung cancer (22) (Fig. 3C and Dataset S3). These data show significant
differences at the gene expression level. Since the set of genes deleted in both models is the same, these differences could be attributable to wide versus restricted cell-type targeting. Further analysis of these markers and molecular pathways could unveil relevant dissimilarities between these 2 types of high-grade neuroendocrine tumors.

Comparison of the 3 subtypes (moLung, moSCLC, and moLCNEC) with the well-established p53/Rb1 mouse model of SCLC described by Schaffer et al. (23) revealed a significant similarity between this model and our moSCLC tumors (SI Appendix, Fig. S5). Additionally, the moLung tumors associated with the Lung subclass in Shaffer’s dataset (SI Appendix, Fig. S5), indicating that

![Fig. 1. Genetic deletion of 4 tumor suppressors in mouse lung epithelial cells results in LCNEC development. Basal cell-type restricted genetic deletion renders SCLC. (A) Schematic of mouse models experiment. Rb1F/F;Rbl1−/−;Trp53F/F;PtenF/F (QKO) mice were infected with Ad5-CMVcre (CMV-QKO) or Ad5-K5cre (K5-QKO). (B) Kaplan-Meier percent tumor-free survival curve of Rb1F/F;Rbl1−/−;Trp53F/F;PtenF/F mice infected with Ad5-CMVcre virus (green line) or Ad5-K5Cre virus (orange line). x axis: latency (weeks after adenovirus injection). Total number of mice analyzed for CMV-QKO, n = 67; K5-QKO, n = 67. (C) The pie charts represent the histopathology spectrum of tumors that arose from CMV-QKO or K5-QKO mice. Total number of tumors for CMV-QKO, n = 886; K5-QKO, n = 537. (D) Hematoxylin–eosin (H&E) representative images and immunohistochemical analyses of the quoted proteins in CMV-QKO LCNEC and human LCNEC (1st and 2nd panels) and K5-QKO SCLC and human SCLC (3rd and 4th panels). (Scale bars, 50 μm.) CHRA, Chromogranin A; CGRP, Calcitonin Gene Related Protein; TTF-1, Thyroid Transcription Factor-1; LCNEC, large-cell neuroendocrine carcinoma; SCLC, small-cell neuroendocrine carcinoma.](https://www.pnas.org/content/116/22/22302)
the sole deletion of the Rbl1 gene does not have a significant impact on gene expression in the normal lung.

Recently, a human LCNEC/SCLC classifier has been described that identifies 4 expression clusters termed classes I to IV, with LCNECs belonging mainly to classes I and II and SCLCs to classes III and IV (4). Unsupervised clustering analysis of the mouse tumors using the LCNEC/SCLC classifier identified 2 clusters of samples corresponding to the moLCNEC and the moSCLC (SI Appendix, Fig. S6B). The analysis of the LCNEC/SCLC classifier genes differentially expressed in moLCNEC versus moSCLC showed that the genes up-regulated in moLCNEC belong to genes up-regulated in class I and II expression clusters, while those up-regulated in moSCLC correspond to class IV up-regulated genes (Fig. 3D, SI Appendix, Fig. S6, and Dataset S4). Analysis of the enrichment in the moLCNEC and moSCLC expression datasets in genes specifically up- or down-regulated in classes I-IV further confirmed their similarity to human LCNEC and SCLC, respectively (SI Appendix, Fig. S6C).

Whole-exome analyses of the mouse tumors generated on average 28.3 million reads per tumor, and each base had 62.4× mean depth of coverage (Dataset S5). Mouse SCLC display higher mutation burden than LCNEC, although far below those reported in human tumors (12, 24) (28.4 and 8.6 transcript altering mutations on average per murine SCLC tumor and LCNEC tumor, respectively) (SI Appendix, Fig. S7 and Dataset S6). Transversions C>G > A>T were not as predominant as in human smoking-associated SCLC (12, 25); however, transitions seem to be of high prevalence in both groups (SI Appendix, Fig. S7). We found a total of 185 somatic alterations in 182 genes (Dataset S5). Some of the altered genes (Ahnak, Thsd7b, Lrrc61) were previously observed in other lung cancers. The reduced mutational burden (reported for SCLC mouse models [24, 26, 27]), together with the low prevalence of mutated genes in each group, suggests that the different tumor types arising in the 2 mouse groups are not due to specific divergent mutational evolution.

Copy number analysis showed more alterations in SCLC than in LCNEC (SI Appendix, Fig. S8); however, the alterations did not recreate in the different samples. Copy number variation hierarchical clustering of 10 tumor samples showed 2 main clusters; samples in each cluster are closer to each other and separated from the others. However, there were not special similarities among tumors of the same type and dissimilarities among tumors of different type, indicating that in terms of genomic copy number variations both types of tumor did not show differences.

**Monitoring Tumors for Preclinical Testing with 18FDG and 68Ga-DOTATOC: Toward Early Lung Cancer Detection and Follow-up.** The fact that the majority of patients with LCNEC and SCLC are diagnosed at advanced stages of the disease makes their therapeutic management particularly difficult. We aimed to develop...
an early noninvasive in vivo method for lung cancer detection and follow-up assessment. Thus, taking advantage of the observed similarities to human samples, we performed combined microPET/computed tomography (CT) analyses in our mice. Control noninfected \((n=3)\), as well as K5-QKO and CMV-QKO mice \((n=10)\) were imaged consecutively with 18F-FDG and 68Ga-DOTATOC. End-point histological analyses revealed the presence of SCLC \((n=4)\) and LCNEC \((n=4)\) tumors among K5-QKO and CMV-QKO mice, respectively. 18F-FDG PET/CT failed to detect these tumors, whereas 68Ga-DOTATOC PET/CT revealed areas of abnormally increased focal uptake as soon as 11 wk in K5-QKO mice (Fig. 4A), showing different standardized uptake value (SUV)max values that ranged from 0.79 to 2.74 \((\text{mean } 1.77 \pm 0.67)\). Immunohistochemistry confirmed the expression of SSTR2 in the tumors (Fig. 4D).

In K5-QKO and CMV-QKO mice, SCLC and LCNEC show clearly higher avidity for 68Ga-DOTATOC than for 18F-FDG. These data denote a remarkably higher sensitivity of the 68Ga-DOTATOC for the detection of high-grade neuroendocrine tumors than the most widely used radiotracer 18F-FDG. These studies show the feasibility of early detection of these tumors due to their avidity of 68Ga-DOTATOC that allows follow-up and monitor changes after therapy. Unfortunately, the present data do not allow us to discern between LCNEC and SCLC tumor types but help to identify and differentiate both high-grade neuroendocrine tumors from other lung malignancies.

**Discussion**

Due to the notable paucity of human material from high-grade neuroendocrine lung tumors from surgery, preclinical mouse models emerge as essential tools for basic and translational research, in particular for LCNEC, since a robust, defined model for this cancer type has not been reported so far. Here we describe 2 accurate mouse models of LCNEC (CMV-QKO) and SCLC (K5-QKO) with unequivocal characteristics resembling their human counterparts. Recently, Gazdar and colleagues showed that some of the previously described models develop LCNEC to a minor extent (28), and Akeno et al. reported the formation of LCNEC along with SCLC (27). The CMV-QKO model presented in this study reveals that, in Rbl1 knockout mice, the somatic inactivation of the tumor suppressors Rb1, Pten, and Trp53 driven by Ad5-CMVcre leads to the formation of LCNEC with histopathological, molecular, and transcriptomic traits strikingly similar to human LCNEC (4). Ad5-CMVcre targeting of lung epithelial cells does not allow the identification of a specific cell type, if any, acting as a cell of origin of LCNEC. Nevertheless, the high incidence, uniform progression, and short latency period of the tumors in this immunocompetent model will facilitate the design and testing of novel tumor intervention strategies against LCNEC and can contribute to future research to identify the cellular origin of this tumor type.

In the QKO mice, Ad5-K5cre virus mediates recombination under steady state conditions in basal cells in which ablation of Rb1, Pten, and Trp53 driven by Ad5-CMVcre leads to the formation of LCNEC with histopathological, molecular, and transcriptomic traits strikingly similar to human LCNEC (4). Ad5-CMVcre targeting of lung epithelial cells does not allow the identification of a specific cell type, if any, acting as a cell of origin of LCNEC. Nevertheless, the high incidence, uniform progression, and short latency period of the tumors in this immunocompetent model will facilitate the design and testing of novel tumor intervention strategies against LCNEC and can contribute to future research to identify the cellular origin of this tumor type.
to lung tumors resembling human SCLC. Several studies have used different combinations of mutations required for SCLC development (mainly based on the Trp53/Rb1 loss) and target widely (by using Ad5-CMVcre virus) or specifically (with Ad5-CGRPcre or Ad5-SPCcre virus) different respiratory epithelial cells, which define the lung lineages from which SCLC arises (reviewed in ref. 9). Among them, neuroendocrine cells have been identified as the predominant cell of origin in SCLC (29). Our K5-QKO model results in SCLC with very high frequency, homogeneity, and short latency, providing evidence that, in homeostatic conditions, keratin 5 expressing basal cells (that can demonstrably act as cell of origin of lung squamous cancer) (8) can give rise to SCLC. In support of this, primary basal epithelial cells can be transformed into small-cell neuroendocrine cancer (30). Taken together, these data confirm SCLC as a tumor type that arises from different cell types that profoundly influence its evolution (31). Additionally, different cell lineages are at the origin of adenocarcinoma (32) and squamous cell carcinoma (5), highlighting the plasticity of diverse putative cancer-initiating cells in the lung.

Reported mouse models show loss of Trp53 and Rb1 as a hallmark of SCLC, otherwise concurring with other genomic alterations (12, 25, 26). Our exome sequencing and CNV analysis did not show particular molecular features exclusive of any type of mouse tumor, and variants observed in our study would be mainly passenger mutations, thus reinforcing the role of the targeted cells in tumor evolution in the QKO mouse model.

In a similar approach, the Rb1, Trp53, Pten triple-knockout model has been used in 2 different studies, rendering either SCLC (1 Pten allele inactivation) or adenocarcinomas with neuroendocrine cell differentiation (both Pten alleles inactivated) when Ad5-CMVcre was used (25), or a mixture of LCNEC, SCLC and NSCLC when neuroendocrine cells were targeted using Ad-CGRPcre (28). Additional Rbl1 loss renders LCNEC as the predominant tumor type in our CMV-QKO mice (Ad5-CMVcre) and SCLC in our K5-QKO mice (Ad5-K5cre), illustrating that both genetic alterations and characteristics of the initiated cells orchestrate the evolution of tumor phenotype (33). The fact that neuroendocrine tumors arise almost exclusively in both CMV-QKO and K5-QKO models highlights the ability of this gene to drive tumors to neuroendocrine phenotype (17). The extended animal survival of 17.5 wk in the Ad5-CMVcre Cui et al. model (25) versus 11 wk in the current CMV-QKO model shows that the additional loss of Rbl1 accelerates tumor onset and supports a role for this gene as a tumor suppressor in lung cancer, as previously described in epidermal tumors (13–15). Interestingly, George et al. confirmed a role of RBL1 in the development of human SCLC (12), and the role of Rbl2, another
member of the Rb family, has been validated in an SCLC animal model (23). 

\[ ^{68}\text{Ga-DOTATOC} \] provides a molecular-imaging system for neuroendocrine tumors. The absence of FDG uptake is an unexpected finding since these tumors are supposed to be \(^{18}\text{F}-\text{FDG}\)-avid because of their high metabolic activity. However, in patients with SCLCs the SUVmax values for \(^{18}\text{F}-\text{FDG}\) PET/CT can differ significantly, ranging from 1.18 to 25.39 (24). Moreover, in mice, measured SUV values in the lungs are greatly influenced by heart proximity to the selected region of interest. The lack of \(^{18}\text{F}-\text{FDG}\) uptake in mice could be explained in part because of the different levels of the glucose transporter, GLUT-1, in pulmonary neuroendocrine tumors (35). As LCNEC and SCLC in CMV-QKO and K5-QKO transgenic mice seem to be \(^{18}\text{F}-\text{FDG}\)-negative, this work presents \(^{68}\text{Ga-DOTATOC}\) as an alternative for early detection and monitoring of primary tumors. Unfortunately, we were not able to discern between LCNEC and SCLC tumors, but to discriminate them from other lung tumor types.

Collectively, our results indicate that the development of lung cancer subtypes appear to be, at least in mice, an interplay between targeted cell type and genotype. While the combination of genetic alterations is crucial for tumor development, this study and monitoring of primary tumors. Unfortunately, we were not expecting since these tumors are supposed to be F-FDG negative, this work presents \(^{68}\text{Ga-DOTATOC}\) as an alternative for early detection and monitoring of primary tumors. Unfortunately, we were not able to discern between LCNEC and SCLC tumors, but to discriminate them from other lung tumor types.

Collectively, our results indicate that the development of lung cancer subtypes appear to be, at least in mice, an interplay between targeted cell type and genotype. While the combination of genetic alterations is crucial for tumor development, this study presents \(^{68}\text{Ga-DOTATOC}\) as an alternative for early detection and monitoring of primary tumors. Unfortunately, we were not able to discern between LCNEC and SCLC tumors, but to discriminate them from other lung tumor types.

ACKNOWLEDGMENTS. We thank Dr. A. Hidalgo (Centro Nacional de Investigaciones Cardiovasculares) for kindly providing the ROSA26R-tTomato mice, the personnel of the Animal Facility at CIEMAT for excellent care of the animals, and Norman Feltz for copyediting the manuscript. This study was funded by cofounded Fondo Europeo de Desarrollo Regional grants from Instituto de Salud Carlos III P12/01959, P115/00099, P118/000263, Red Temática de Investigación Cooperativa en Salud RD12/0036/0009, and CIBERONC CB/16/00228, by Ministerio de Economía y Competitividad SAF2015-66015-R, and by PIE1500076.

1. W. D. Travis et al., WHO Panel, The 2015 world health organization classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J. Thorac. Oncol. 10, 1243–1260 (2015).

2. N. Rekhtman et al., Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin. Cancer Res. 22, 3618–3629 (2016).

3. T. Miyoshi et al., Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin. Cancer Res. 23, 757–765 (2017).

4. J. George et al., Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat. Commun. 9, 1948–1061 (2018).

5. A. Sánchez-Danés, C. Blanpain, Deciphering the cells of origin of squamous cell carcinomas. Nat. Rev. Cancer 18, 549–561 (2018).

6. J. R. Rock et al., Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc. Natl. Acad. Sci. U.S.A. 106, 12771–12775 (2009).

7. D. T. Montoro et al., A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature 560, 319–324 (2018).

8. G. Ferone et al., SOX2 is the determining oncogenic switch in promoting lung squamous cell carcinoma from different cells of origin. Cancer Cell 30, 519–532 (2016).

9. E. A. Semenova, R. Nagel, A. Berns, Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev. 29, 1447–1462 (2015).

10. I. Kayani et al., A comparison of \(^{68}\text{Ga-DOTATATE} \) and \(^{18}\text{F-FDG}\) PET/CT in pulmonary neuroendocrine tumors. J. Nucl. Med. 50, 1927–1932 (2009).

11. B. Venkitaraman, S. Karunanithi, A. Kumar, G. C. Khilnani, R. Kumar, Role of \(^{68}\text{Ga-DOTATOC}\) PET/CT in initial evaluation of patients with suspected bronchopulmonary carcinoids. Eur. J. Nucl. Med. Mol. Imaging 41, 856–864 (2014).

12. J. George et al., Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47–53 (2015).

13. S. Ruiz et al., Unique and overlapping functions of \(p16\) and \(p107\) in the control of proliferation and differentiation in epidermis. Development 131, 2737–2748 (2004).

14. M. F. Lara et al., \(p107\) acts as a tumor suppressor in \(p16\)-deficient epidermolysis. Mol. Carcinog. 47, 101–113 (2008).

15. C. Costa et al., A novel tumor suppressor network in squamous malignancies. Sci. Rep. 2, 828 (2012).

16. M. DuPage, A. L. Dooley, T. Jacks, Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064–1072 (2009).

17. S. Lázaro et al., Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation. Oncotarget 8, 43733–4386 (2017).

18. C. Rubio et al., CDK4/6 inhibitor as a novel therapeutic approach for advanced bladder cancer independently of \(RBL1\) status. Clin. Cancer Res. 25, 390–402 (2019).

19. T. J. Lynch, J. F. Engelhardt, Progenitor cells in proximal airway epithelial development and regeneration. J. Cell. Biochem. 115, 1637–1645 (2014).

20. L. Madisen et al., A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133–140 (2010).

21. P. Soriani, Generalized Iac expression with the ROSA26 Cre reporter strain. Nat. Genet. 21, 70–71 (1999).

22. H. Dosepo et al., PTH3 controls lung metastasis and resistance to EGFR inhibitors through TGFα. Cancer Res. 78, 1805–1819 (2018).

23. B. E. Schaffer et al., Loss of P130 regulates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res. 70, 3877–3883 (2010).

24. M. Pfeifer et al., Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104–1110 (2012).

25. M. Gui et al., PTEN is a potent suppressor of small cell lung cancer. Mol. Cancer Res. 12, 654–659 (2014).

26. D. G. McFadden et al., Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156, 1298–1311 (2014).

27. N. Akeno et al., Cell of origin of small cell lung cancer: Inactivation of \(Trp53\) and \(Rbl1\) in distinct cell types of adult mouse lung. Genes Dev. 29, 1447–1462 (2015).

28. J. W. Park et al., Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362, 91–95 (2018).

29. D. Yang et al., Intertumoral heterogeneity in SCLC is influenced by the cell type of origin. Cancer Discov. 8, 1316–1331 (2018).

30. K. D. Sutherland et al., Cell of origin of small cell lung cancer: Inactivation of Trp53 and Rbl1 in distinct cell types of adult mouse lung. Cancer Cell 19, 754–764 (2011).

31. Y. S. Song et al., Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 61, 54–60 (2008).